{
  "id": 14651253,
  "title": "Biocon Chair: AI in Clinical Trials Is the Holy Grail",
  "url": "https://urgent.news/2026/10/15/biocon-chair-ai-in-clinical-trials-is-the-holy-grail",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-15T08:13:27.000Z",
  "source": {
    "name": "Bloomberg",
    "slug": "bloomberg",
    "url": "https://www.bloomberg.com/news/videos/2026-10-15/biocon-chair-ai-in-clinical-trials-is-the-holy-grail-video"
  },
  "original_language": "en",
  "account": null,
  "summary": "Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its current top-five global ranking. Speaking on the sidelines of the Bloomberg New Economy Forum in New Delhi, Mazumdar-Shaw added that while AI accelerates molecular discovery, the…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}